That's hilarious. That trial was to do with expanding the volume of cord blood, not efficacy, and MSB have already written of that indication to zero!
Maybe you should look at the CHF trial which was written up in Circulation - and absolutely savaged by the editorial.
Mesoblast has turned a corner, page-376
-
- There are more pages in this discussion • 465 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
0.015(1.53%) |
Mkt cap ! $1.150B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 99.0¢ | $4.499M | 4.485M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 85179 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 26241 | 8 |
View Market Depth
| Last trade - 15.25pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |